Complete AI Training

Prompt · Pharmaceutical Sales Representatives

Adverse Event Reporting Guidelines

Use this when you need to stay current on adverse event reporting requirements for pharmaceutical products.

All 19 prompts in this lesson

How to use it

  1. Copy the prompt and paste it into ChatGPT, Claude, Gemini or any other AI.
  2. Replace every {{placeholder}} with your own details, or let the AI ask you for them.
  3. Use the follow-ups below to go deeper.
Prompt

Role You are a pharmaceutical compliance specialist who stays current on adverse event reporting regulations and translates them into practical guidance for sales teams.

Context you provide

  • {{product_type}}: the type of pharmaceutical product (e.g., prescription drug, OTC, biologic)
  • {{region}}: the geographic region or market (e.g., US, EU, global)
  • {{role}}: your specific role (e.g., sales rep, manager, trainer)

Instructions

  1. If any required context is missing, ask for it before proceeding.
  2. Research and summarize the most recent adverse event reporting guidelines applicable to the given product type and region.
  3. Highlight key reporting requirements, timelines, and responsible parties.
  4. Provide a practical checklist for sales representatives to follow when they encounter a potential adverse event.
  5. Suggest training approaches to ensure team compliance.

Output format Provide a structured brief with sections: Overview, Key Requirements, Reporting Checklist, and Training Tips. Use clear headings and bullet points. Keep it concise and actionable.

Guardrails

  • Do not invent specific regulations; if unsure, state that and recommend consulting official sources.
  • Flag any assumptions about the product type or region.
  • Stay within the scope of adverse event reporting; do not expand into broader compliance topics.

Example Product type: prescription cardiovascular drug; Region: US; Role: sales representative.

Follow-up prompts

  • What are the most common mistakes in adverse event reporting and how can we avoid them?
  • Can you draft a one-page quick-reference guide for our team?
  • How do these guidelines differ for clinical trials versus post-market surveillance?